A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

This study is evaluating a PET scan imaging agent called fluciclovine in prostate cancer patients whose previous PSMA-PET scan (another imaging test) came back negative or inconclusive, but whose PSA levels suggest the cancer may have come back after treatment. **You may be eligible if...** - You are a male aged 18 or older - You have had prostate cancer treated with surgery (radical prostatectomy) or radiation therapy - Your PSA level is rising in a way that suggests cancer recurrence (specific PSA thresholds apply depending on your prior treatment) - Your prior PSMA-PET scan was negative or inconclusive **You may NOT be eligible if...** - You have received androgen deprivation therapy (hormone therapy) within the past 3 months - You have a medical condition that the investigator believes would compromise the study data or your safety Talk to your doctor to see if this trial is right for you.